Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

This study tests whether adding rocbrutinib (a BTK inhibitor, which blocks a protein that helps certain cancers grow) to a standard chemotherapy regimen called R-CHOP improves outcomes for people newly diagnosed with certain B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). **You may be eligible if...** - You have been newly diagnosed with DLBCL, MCL, or MZL confirmed by biopsy - You have not previously received any treatment for this cancer - You have at least one measurable tumor on scans - You are in good enough physical condition (ECOG 0–2) - Your organ function is adequate **You may NOT be eligible if...** - You have already received treatment for this lymphoma - You have significant bleeding problems or are on anticoagulants - You have active hepatitis B, hepatitis C, or HIV - You are pregnant or breastfeeding - You have significant heart rhythm problems Talk to your doctor to see if this trial is right for you.